![Traditional sequential phase versus seamless expansion trial design. a... | Download Scientific Diagram Traditional sequential phase versus seamless expansion trial design. a... | Download Scientific Diagram](https://www.researchgate.net/publication/321285582/figure/fig2/AS:960010049835031@1605895640220/Traditional-sequential-phase-versus-seamless-expansion-trial-design-a-In-the-traditional.gif)
Traditional sequential phase versus seamless expansion trial design. a... | Download Scientific Diagram
![Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01632-2/MediaObjects/41416_2021_1632_Fig1_HTML.png)
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer
Bavdegalutamide (ARV-110): Phase 1 Dose Escalation and Interim ARDENT Phase 2 Dose Expansion Trial Results
![Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X](https://pbs.twimg.com/media/CzqZ9KGXUAAXpDN.jpg)
Bertrand Delsuc on X: "@BiotechRadar CUARt123 AML: RP2D definition, extensive DLT recording (differences vs ALL), dose expansion, risks assessment https://t.co/aDIcKjyNon" / X
![Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals](https://pub.mdpi-res.com/vaccines/vaccines-11-00781/article_deploy/html/images/vaccines-11-00781-g001.png?1680494606)
Vaccines | Free Full-Text | Why Reaching Zero-Dose Children Holds the Key to Achieving the Sustainable Development Goals
![Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419322458-gr2.jpg)
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect
![Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2021/edbk.2021.41/edbk_319783/20210531/images/large/edbk_319783-table1.jpeg)
Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book
![Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram](https://www.researchgate.net/publication/264640460/figure/fig1/AS:282055268159519@1444258624826/Translational-phase-I-study-with-biomarker-defined-end-points-Phase-I-oncology-studies.png)
Translational phase I study with biomarker-defined end points. Phase I... | Download Scientific Diagram
![First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine](https://www.thelancet.com/cms/asset/2e367137-80c0-40c6-9ddd-bcd689ba8a67/gr1.jpg)
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - eClinicalMedicine
![Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram](https://www.researchgate.net/publication/46403694/figure/fig2/AS:667189245931545@1536081720859/Inter-patient-and-intra-patient-dose-escalation-strategy-Patients-were-sequentially.png)
Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram
![Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-023-02297-5/MediaObjects/41591_2023_2297_Fig1_HTML.png)
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results | Nature Medicine
![Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation](https://www.frontiersin.org/files/MyHome%20Article%20Library/1086258/1086258_Thumb_400.jpg)
Frontiers | Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation
![Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419322458-gr3.jpg)